Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus ...

The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.

Researchers have used artificial intelligence to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types. Their new approach opens the ...

Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...

The Japanese government, industry and academia are deliberating health care policies and initiatives to boost Japan’s role in ...

A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.

Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...

As December 2022 closed out, Pfizer announced positive top-line results from its phase 3 BENEGENE-2 study evaluating fidanacogene elaparvovec (SPK-9001), its investigational gene therapy for ...

Scientists at the Icahn School of Medicine at Mount Sinai, in collaboration with colleagues in the field, have developed an ...

Spark Therapeutics is on the cusp of gaining the first ever approval for a gene therapy from the FDA, a groundbreaking treatment which restores vision to children and adults with a rare inherited ...

The US embassy in Sri Lanka has issued a warning of a potential attack on the popular surfing spot Arugam Bay, prompting enhanced security for tourists. This follows social media calls to boycott ...